Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae
Braz. j. infect. dis
;
15(2): 167-169, Mar.-Apr. 2011. ilus, tab
Article
in English
| LILACS
| ID: lil-582428
ABSTRACT
The objective of this study was to evaluate the susceptibility to cefepime of a large group of ESBL- producing enterobacteria recently isolated in a Brazilian teaching hospital . The study included 280 strains of ESBL-producing enterobacteria, isolated between 2005 and 2008. The presence of the genes blaCTX-M, blaTEM and blaSHV was determined by PCR and confirmed by nucleotide sequencing. Susceptibility testing for cefepime was performed by disc-diffusion, agar dilution method and E-test®. Among the isolates, 34 (12.1 percent) presented a cefepime inhibition zone > 21 and MIC < 8 mg/L by agar dilution and E-strip methods. The use of cefepime for the treatment of infections caused by ESBL-producing bacteria has been controversial. Some studies of PD/PK show the probability of achieving the required PD parameters for cefepime, when the MICs were < 8 mg/L, whereas others have reported therapeutic failure with the same MIC. Additional data is essential to come to terms about the report and treatment with cefepime in ESBL-producing organisms especially when these microorganisms are isolated from sterile sites and from critically ill patients.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Beta-Lactamases
/
Cephalosporins
/
Enterobacteriaceae
/
Anti-Bacterial Agents
Limits:
Humans
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2011
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade Federal de São Paulo/BR
/
Universidade Federal do Paraná/BR
Similar
MEDLINE
...
LILACS
LIS